Intervention: Ruxolitinib Phosphate
Trial phase: Phase 2
SMILES: N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Investigational cream to 1 location; vehicle cream to 2nd location

Ruxolitinib 1.5% cream: Topical formulation of ruxolitinib, a Janus kinases (JAK) 1/2 inhibitor.
Eligibility criteria:
INCLUSION CRITERIA:
Patients must have histologically confirmed epidermal Chronic Graft Versus Host Disease (cGVHD) including lichen planus-like, papulosquamous, and erythematous cGVHD with clinical involvement at 2 separate body regions (e.g. right forearm and left forearm).
Patients must have measurable disease, defined as at least 2 areas of cutaneous, nonulcerated, epidermal cGVHD involvement. Each site must involve at least 0.5% body surface area (1 palm equivalent) and cannot be a site of current or previous nonmelanoma skin cancer (NMSC).
Stable immunosuppressant or immunomodulatory systemic cGVHD treatment, including phototherapy and extracorporeal photopheresis, for 4 weeks prior to enrollment.
Age greater than or equal to 12 years. There is no available safety or adverse events data available for children younger than 12 years of age.
Karnofsky or Lansky greater than or equal to 60

Patients must have normal organ and marrow function as defined below:

absolute neutrophil count greater than or equal to 1,000/mcL
platelets greater than or equal to 50,000/mcL
hemoglobin > 9 g/dL
total bilirubin <1.5X institutional upper limit of normal except if known history of Gilbert's disease
Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT)/alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) less than or equal to 5X institutional upper limit of normal
creatinine clearance greater than or equal to 50 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal.
Willingness to comply with twice daily application of 2 different creams to 2 separate, prespecified sites.
The effects of ruxolitinib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

Patients concurrently receiving a Janus kinase (JAK) inhibitor (topical or systemic).
Patients receiving any other investigational agents.
Patients concurrently taking oral fluconazole.
Patients concurrently taking strong Cytochrome P450 3A4 (CYP3A4) inhibitors.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or other agents used in study.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection including Epstein-Barr virus (EBV), Cytomegalovirus (CMV), human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Pregnant women are excluded from this study because ruxolitinib is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ruxolitinib, breastfeeding should be discontinued if the mother is treated with ruxolitinib. These potential risks may also apply to other agents used in this study.
Recurrent or progressive malignancy requiring anticancer treatment.
Other cancer (except that for which hematopoietic cell transplantation (HCT) was performed) within 2 years of study entry, except nonmelanoma skin cancer or carcinoma in situ of the breast, uterus, or cervix.
History of cutaneous malignancy at target lesion site.
Any participant who, in the investigator's opinion, would be unable to comply with study requirements or for whom participation may pose a greater medical risk.